Enlyton, Ltd. Awarded National Cancer Institute SBIR Phase I Contract for Tumor Targeting Agent for SPECT Imaging of Cancer
9/18/2012 9:59:37 AM
COLUMBUS, Ohio--(BUSINESS WIRE)--Enlyton, Ltd., a technology leader in the development of cancer-specific tumor targeting agents for use in molecular imaging, has been awarded a Phase I Small Business Innovation Research (SBIR) contract in the amount of $249,525 from the National Cancer Institute (NCI). The Phase I contract, which will cover approximately 10% of the total project cost, will be used to complete pre-clinical development of Enlyton’s antibody-based tumor targeting agent for SPECT imaging of adenocarcinomas (e.g., colorectal, esophageal, stomach, lung, ovarian, pancreatic).
comments powered by